Abstract:OBJECTIVE:To evaluate effect of duration of clopidogrel use on clinical follow-up outcomes in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. METHODS:A total of 214 patients with acute myocardial infarction undergoing primary percutaneous coronary intervention between January 2005 to December 2007 were enrolled. All patients were divided into two groups by duration of clopidogrel use: <1 year group (n=59) and > or =1 years group (n=155). Baseline characteristics [age, gender, angiographic characteristics, Killip classification, LVEF (left ventricular ejection fraction) , CK (creatine kinase), CK-MB, CTnI (cardiac troponin-I), hemoglobin levels and history of hypertension, diabetes, hyperlipidemia, obesity and smoking] of two groups were collected. Clinical follow-up end-point was major adverse cardiac event (MACE) including death, acute myocardial infarction, stent thrombosis and stent restenosis. Clinical follow-up duration was 41.6 +/- 16.3 months. MACE occurred in 28 patients. RESULTS:Rates of male, infarction site, infarction relative artery, multivessel disease, Killip classification (class I), aspirin use and history of smoking, obesity, hypertension and hyperlipidemia were not different (P > 0.05) in duration of clopidogrel use <1 year group and > or =1 years group. Average LVEF, hemoglobin levels and rate of drug-eluting stents were significantly lower in duration of clopidogrel use <1 year group than that in duration of clopidogrel use > or =1 years group (P < 0.0001, P < 0.0001, P = 0.0065). Average CK, CK-MB, CTnI were significantly higher in duration of clopidogrel use > or =1 years group than that in duration of clopidogrel use <1 year group (P < 0.0001). Rate of diabetes and average age were significantly higher in duration of clopidogrel use <1 year group than that in duration of clopidogrel use > or =1 years group (P = 0.0190, P < 0.0001). Incidence of MACE in follow-up period was significantly lower in duration of clopidogrel use > or =1 years group than that in duration of clopidogrel use < 1 year group (6.45% vs. 30.51%, P < 0.01). After stopping clopidogrel use, incidence of MACE in followup period was significantly lower in duration of clopidogrel use > or =1 years group than that in duration of clopidogrel use <1 year group (2.58% vs. 20. 34%, P < 0.01). CONCLUSION:Primary percutaneous coronary intervention is an effective therapeutic method. Incidence of MACE in follow-up period was significantly lower in duration of clopidogrel use > or =1 years group than that in duration of clopidogrel use <1 year group. Duration of clopidogrel use may influence clinical outcomes in follow-up period in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention.

Study of atorvastatin and clopidogrel interaction in patients undergoing coronary stenting in a long-time treatment

[Comparison on Long-Term Effects of Atorvastatin or Pravastatin Combined with Clopidogrel for Patients Undergoing Coronary Stenting: a Randomized Controlled Trial].

[The Antiplatelet Effect of Clopidogrel is Not Attenuated by Statin Treatment in Patients with Acute Coronary Syndromes Undergone Coronary Stenting].

Clinical effect of ticagrelor administered in acute coronary syndrome patients following percutaneous coronary intervention.

[Effects of Proton Pump Inhibitors on In-Stent Restenosis in Patients Receiving Clopidogrel: a Retrospective Analysis].

Effect of different duration of clopidogrel pretreatment on platelet activation in patients undergoing stenting

[Effect of duration of clopidogrel use on clinical follow-up outcomes in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention].

Efficacy and Safety of Serial Atorvastatin Load in Chinese Patients Undergoing Elective Percutaneous Coronary Intervention: Results of the ISCAP (intensive Statin Therapy for Chinese Patients with Coronary Artery Disease Undergoing Percutaneous Coronary Intervention) Randomized Controlled Trial

Effects of Triple Antiplatelet Therapy on Patients Undergone Coronary Artery Stenting

Optimal antiplatelet therapy after coronary stenting,a single-center randomized controlled pilot study

A retrospective study of the safety and efficacy of clopidogrel versus aspirin monotherapy one year after coronary stent implantation

Effect of Different Doses of Cilostazol Intensive Antiplatelet Therapy on the Patients with High On-treatment Platelet Reactivity after Coronary Stent Implantation

Impact of serum lipid level on residual platelet reactivity in patients with non-ST elevation acute coronary syndrome receiving dual anti-platelet therapy after percutaneous coronary intervention

The Dynamic Effect of Non-CYP3A4-Metabolized and CYP3A4-Metabolized Statins on Clopidogrel Resistance in Patients With Cerebral Infarction

Effects of Intensive Antiplatelet Therapy for Patients with High On-Treatment Platelet Reactivity after Coronary Stent Implantation

Efficacy of High-dose Statins Pretreatment on PCI-related Inflammation and Myocardial Injury

The different-dose simvastatin's effect on the platelet activity after the elderly patients' treatment by PCI

Long-term effect of triple antiplatelet therapy for diabetic patients after percutaneous coronary intervention

Impact of high loading-dose atorvastatin pre-treatment before primary percutaneous coronary intervention on coronary flow in patients with ST segment elevation myocardial infarction

Short-term Outcomes of High Loading Dose Clopidogrel Pretreatment Before Coronary Stenting in Patients with Acute Coronary Syndromes

Clinical Study of Atorvastatin Combined with Clopidogrel in Patients with Acute Cerebral Infarction